Rare and Orphan Diseases - Global Oncology Academy

17-32 of 58

Optimizing Care for Older Adults With FLT3-Mutated AML
Optimizing Care for Older Adults With FLT3-Mutated AML
Global Oncology Academy
Optimizing Care for Older Adults With FLT3-Mutated AML
Ryan Quigley; Nicholas Short, MD
- Ryan Quigley
- Nicholas Short, MD
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
Project Oncology®
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
Jennifer Caudle, DO, FACOFP; Mansi R. Shah, MD
- Jennifer Caudle, DO, FACOFP
- Mansi R. Shah, MD
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Project Oncology®
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Daniela Molena, MD
- Daniela Molena, MD
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstracts
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Ryan Quigley; Kathrin M. Bernt, MD
- Ryan Quigley
- Kathrin M. Bernt, MD
- Rushabh Mehta, BS
- Fatemeh Alikarami
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
- Ryan Quigley
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
- Ryan Quigley
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP; Luhua (Michael) Wang, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Charles Turck, PharmD, BCPS, BCCCP; Jonathon B. Cohen, MD, MS
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Balazs Halmos, MD, MS
- Balazs Halmos, MD, MS

2/4